Treatment interruptions and discontinuations among patients with stage III unresectable non-small cell lung cancer treated with durvalumab at the Veterans Health Administration.

被引：0
|
作者：
Alkadimi, Munaf
Moore, Amanda
Frei, Christopher R.
Reveles, Kelly R.
Brannman, Lance
Cotarla, Ion
Frankart, Andrew
Mulrooney, Tiernan
Datta, Paromita
Whitehead, Jennifer
Franklin, Kathleen
Reichelderfer, Renee
Williams, Madison H.
Williams, Ryan A.
Smith, Sarah Allison
Jones, Xavier
Nooruddin, Zohra
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA
[2] Univ Texas Austin, Coll Pharm, Austin, TX USA
[3] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[4] Univ Texas Hlth San Antonio, San Antonio, TX USA
[5] AstraZeneca, Gaithersburg, MD USA
[6] Univ Cincinnati, Dept Radiat Oncol, Cincinnati, OH USA
[7] VA Hosp, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8554
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durvalumab treatment initiation delays in patients with unresectable stage III non-small cell lung cancer treated at Veterans Health Administration facilities.
    Datta, Paromita
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Alkadimi, Munaf
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
    Moore, Amanda M.
    Nooruddin, Zohra
    Reveles, Kelly R.
    Koeller, Jim M.
    Whitehead, Jennifer M.
    Franklin, Kathleen
    Datta, Paromita
    Alkadimi, Munaf
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew J.
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    ONCOLOGIST, 2023, 28 (09): : 804 - 811
  • [3] Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non-small cell lung cancer treated at Veterans Health Administration facilities.
    Moore, Amanda
    Nooruddin, Zohra
    Reveles, Kelly R.
    Datta, Paromita
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
    Moore, Amanda M.
    Nooruddin, Zohra
    Reveles, Kelly R.
    Datta, Paromita
    Whitehead, Jennifer M.
    Franklin, Kathleen
    Alkadimi, Munaf
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah
    Reichelderfer, Renee
    Cotarla, Ion
    Brannman, Lance
    Frankart, Andrew
    Mulrooney, Tiernan
    Hsieh, Kristin
    Simmons, Daniel J.
    Jones, Xavier
    Frei, Christopher R.
    CURRENT ONCOLOGY, 2023, 30 (09) : 8411 - 8423
  • [5] Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities
    Burton, Elizabeth M.
    Moore, Amanda
    Nooruddin, Zohra
    Cotarla, Ion
    Simmons, Daniel
    Davis, Laura
    Reveles, Kelly R.
    Datta, Paromita
    Souza, Gabriel Roman
    Irabor, Omoruyi Credit
    Franklin, Kathleen
    Jones, Xavier
    Frei, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [7] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [8] Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer
    Anna Hung
    Kyung Min Lee
    Julie A. Lynch
    Yanhong Li
    Pradeep Poonnen
    Olga V. Efimova
    Bradley J. Hintze
    Trudy Buckingham
    Candice Yong
    Brian Seal
    Michael J. Kelley
    Shelby D. Reed
    BMC Cancer, 21
  • [9] Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer
    Hung, Anna
    Lee, Kyung Min
    Lynch, Julie A.
    Li, Yanhong
    Poonnen, Pradeep
    Efimova, Olga V.
    Hintze, Bradley J.
    Buckingham, Trudy
    Yong, Candice
    Seal, Brian
    Kelley, Michael J.
    Reed, Shelby D.
    BMC CANCER, 2021, 21 (01)
  • [10] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
    Furuhashi, K.
    Hataji, O.
    Nakamura, Y.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Fujiwara, K.
    Nishii, Y.
    Taguchi, O.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
12345